A pharmaceutical formulation, comprising a phosphatidylcholine product of formula (I), wherein R1 is the residue of a saturated or unsaturated fatty acid with 12-24 carbon atoms, and R2 is the residue of a saturated or unsaturated fatty acid with 12-24 carbon atoms, and wherein the phosphatidylcholine product (PC) contains the following amounts of fatty acids: 55 -72 linoleic acid； 10 -18 palmitic acid； 07 -15 oleic acid； 02 -08 linolenic acid； 02 -08 stearic acid, and at least one excipient for delayed release, can be used for the improved treatment of ulcerative colitis.
